This website uses cookies to enhance the user experience.
||
INVEN2 AS

INVEN2 AS995 495 899

Limited company
Gaustadalléen 21 0349 OSLO, Norge

INVEN2 AS

Inven2 - Innovasjon innen forskning og utvikling - Kliniske studier
Inven2 omgjør forskning og kunnskap til samfunnsnyttige produkter og tjenester. Inven2 sin kjernevirksomhet er innovasjon.

Links

Organization

CEO
OK

Ole Kristian Hjelstuen1962

Chairman of the board
TE

Tom Edward Pike1960

Years since formation
15 years
since May 15, 2010
Type
Limited company
VAT registered
Yes
Number of employees
32

Ownership

Number of shares and share classes
10,000
1 share class
Total number of shareholders
2
companies
Belongs to group of

Financials

Total operating income 2024
83,852,000
NOK
Annual total result 2024
-14,796,000
NOK
Total equity 2024
178,779,000
NOK
Last update: Sep 9, 2025

Management

Management / administration

NameRoleShares
OK

Ole Kristian Hjelstuen

1962

Managing Director/CEO-

Board

NameRoleShares
TE

Tom Edward Pike

1960

Chairman-
IS

Inger Sandlie

1953

Board Member-
EB

Erlend Bremertun Smeland

1955

Board Member-
IK

Idar Kreutzer

1962

Board Member-
LK

Lars Kristian Eikvar

1960

Board Member-
BE

Benedicte Elisabeth Bakke Agerup

1964

Board Member-
AM

Anne Marie Tissé Bjørgo

1976

Board Member-
MR

Mona-Elisabeth Rootwelt-Revheim

1969

Board Member-
JP

Jens Petter Berg

1960

Board Member-

Others

NameRoleShares
P
PRICEWATERHOUSECOOPERS AS
Auditor-
Last update: Jun 23, 2025

Ownership

Company shareholders

NameShare classTotal number of sharesShare
U
UNIVERSITETET I OSLO
Ordinary shares
5,000
50 %
O
OSLO UNIVERSITETSSYKEHUS HF
Ordinary shares
5,000
50 %

Shares owned by the INVEN2 AS

NameShare classTotal number of sharesShare
N
NEONATAL ANALYTICS AS
Ordinary shares
30,000
100 %
M
MENTALESE AS
Ordinary shares
30,000
100 %
I
IMMUNOQUEST THERAPEUTICS AS
Ordinary shares
18,000
60 %
B
BALDUR COATINGS AS
Ordinary shares
50,000
50 %
D
DHEALTH AS
Ordinary shares
124,271
40.56 %
A
AGIANA PHARMACEUTICALS AS
Ordinary shares
13,364
37.07 %
P
PROFMOF AS
Ordinary shares
34,300
33.46 %
A
ALEAP AS
G-shares
30,000
33.33 %
C
CARDINOR AS
Ordinary shares
445,000
32.6 %
S
SERCA PHARMACEUTICALS AS
Ordinary shares
234,032
26.13 %
F
FASTLEGEPORTALEN AS
Ordinary shares
60
20 %
C
CFIRE AS
Ordinary shares
30,000
20 %
S
SPORTECH AS
Ordinary shares
30,000
20 %
S
SOMSAGT AS
Ordinary shares
23,333
19.72 %
R
RAFX TECHNOLOGIES AS
Ordinary shares
5,372
17.91 %
Z
ZELLUNA IMMUNOTHERAPY AS
NO0010820731
1,602,500
13.08 %
P
PONE BIOMETRICS AS
Ordinary shares
2,107,569
12.99 %
P
PRE VENTION AS
Class B shares
5,000
12.5 %
P
PRE DIAGNOSTICS AS
NO0010754757
51,133
11.93 %
U
UNIGEO AS
Ordinary shares
15,000
11.66 %
H
HOLOCARE AS
Ordinary shares
21,322
11.29 %
F
FOODCAPTURE AS
Ordinary shares
48,413
11.01 %
L
LUNDELAB AS
Ordinary shares
111
9.99 %
N
NEXTEQ AS
NO0010891310
258,547
6.78 %
P
PROSA SECURITY AS
Ordinary shares
41,572
6.32 %
O
OSLO CANCER CLUSTER INCUBATOR AS
Ordinary shares
13,533
5.83 %
A
ADJUTEC PHARMA AS
Ordinary shares
2,648
5.39 %
N
NORDIC BRAIN TECH AS
Ordinary shares
8,877
5.02 %
O
ODI MEDICAL AS
NO0010858343
7,592
4.5 %
E
EPIGUARD AS
Ordinary shares
17,760
4.46 %
C
COMPENSO MEDTECH AS
Ordinary shares
5,224
4.46 %
Z
ZELLUNA ASA
NO0010851603
1,265,139
3.68 %
B
BIOMOLEX AS
NO0010162266
27,432
3.3 %
P
PHARMASUM THERAPEUTICS AS
Ordinary shares
103,448
3.27 %
M
MINE OPPLYSNINGER AS
Ordinary shares
900
3 %
T
TRYIO AS
Ordinary shares
900
3 %
E
ENCE AS
Ordinary shares
3,000
3 %
B
BEEP SYSTEMS AS
Ordinary shares
900
3 %
S
STILY AS
Ordinary shares
9,000
3 %
N
NEXTERA AS
NO0010848534
116,471
2.84 %
C
CURRENT ECO AS
Ordinary shares
38,722
2.32 %
D
DOMORE DIAGNOSTICS AS
Ordinary shares
1,000,000
1.76 %
E
ELLIPTIC LABORATORIES ASA
NO0010722283
1,441,670
1.37 %
S
STARTUPLAB FOUNDERS FUND V AS
A-shares
120,000
1.27 %
P
PERSON-AIZ AS
Ordinary shares
4,913
1.03 %
O
OSTOMYCURE AS
Ordinary shares
3,315,466
0.84 %
P
PROPHYLIX PHARMA HOLDING AS
A-shares
3,333
0.55 %
D
DISPUTAS AS
Ordinary shares
900
0.43 %
O
ONCOINVENT ASA
NO0010779341
210,261
0.23 %
T
THOR MEDICAL ASA
NO0010597883
541,247
0.19 %
N
NOVELDA AS
NO0010733454
3,396
0.18 %
Last update: Jun 2, 2025

Group structure

  • INVEN2 AS
    Total operating income 2024: NOK 83,852,000
    Operating profit 2024: NOK -26,817,000
    Employees: 32

Financials

in NOK

Summary

Year2024202320222021
Total operating income
83,852,000
81,985,000
158,267,000
110,272,000
Annual Total Result
-14,796,000
-2,245,000
54,373,000
18,608,000
Total assets
318,450,000
357,761,000
361,179,000
293,288,000
Total liabilities
139,671,000
164,186,000
165,359,000
151,841,000
Total equity
178,779,000
193,575,000
195,820,000
141,447,000

P&L

Year2024202320222021
Total operating income
83,852,000
81,985,000
158,267,000
110,272,000
Total operating costs
110,669,000
99,811,000
90,840,000
99,968,000
Operating result
-26,817,000
-17,826,000
67,428,000
10,304,000
Financial income/costs
14,943,000
17,675,000
-6,898,000
4,630,000
Profit before tax
-11,875,000
-151,000
60,530,000
14,934,000
Total tax & extraordinary income/cost
2,921,000
2,094,000
6,157,000
-3,674,000
Annual Total Result
-14,796,000
-2,245,000
54,373,000
18,608,000

Balance overview

Year2024202320222021
Total fixed assets
110,602,000
118,647,000
113,744,000
116,988,000
Total current assets
207,848,000
239,114,000
247,435,000
176,301,000
Total assets
318,450,000
357,761,000
361,179,000
293,288,000
Short term debt
73,011,000
93,629,000
88,683,000
78,813,000
Long term debt
0
0
0
0
Total liabilities
139,671,000
164,186,000
165,359,000
151,841,000
Contributed capital
40,000,000
40,000,000
40,000,000
40,000,000
Retained earnings
138,779,000
153,575,000
155,820,000
101,447,000
Total equity
178,779,000
193,575,000
195,820,000
141,447,000
Total equity and liabilities
318,450,000
357,761,000
361,179,000
293,288,000

Classification

Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
1120
Public incorporated enterprises, owned by central government